Synaffix, a Lonza subsidiary, has signed licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma for advancing antibody-drug conjugate (ADC) programs. These deals reflect Synaffix's growing presence in the ADC space, with potential milestone payments and royalties involved.